About
About this Poster:
BFKB8488A is a humanized, effector-less, bispecific antibody designed to activate the receptor for fibroblast growth factor 21 (FGF21) in adipose tissue, the FGFR1/Klothoß complex. Preclinical studies demonstrated that BFKB8488A largely recapitulates the metabolic actions of recombinant FGF21 in rodents and non-human primates. This Phase 1, first-in-human study was performed with obese but otherwise healthy subjects. The primary objectives were safety, tolerability, and pharmacokinetics. Additionally, insulin, glucose, lipids, and other metabolic markers were measured.
![Weight loss unrelated to decrease in calorie intake after a single dose of a bispecific antibody to FGFR1/Klothoβ in obese subjects thumbnail](https://prosciento.com/wp-content/uploads/2022/01/poster-22.png)